Duchenne Muscular Dystrophy (DMD) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Duchenne Muscular Dystrophy (DMD) Market Outlook

Thelansis's "Duchenne Muscular Dystrophy (DMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Duchenne Muscular Dystrophy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Duchenne Muscular Dystrophy (DMD) Overview

Duchenne muscular dystrophy (DMD) is a severe X-linked recessive neuromuscular disorder caused by DMD gene mutations abolishing dystrophin production, triggering progressive muscle membrane fragility, chronic inflammation, and fibrofatty replacement of skeletal, cardiac, and respiratory musculature. Boys present in early childhood with proximal weakness, Gowers sign, calf pseudohypertrophy, and delayed motor milestones, progressing to loss of ambulation by early adolescence, followed by respiratory insufficiency and cardiomyopathy as principal causes of mortality. Diagnosis integrates markedly elevated creatine kinase, dystrophin immunostaining, and confirmatory DMD genetic sequencing. Corticosteroids remain the therapeutic cornerstone, with deflazacort and vamorolone offering differing tolerability profiles. Exon-skipping antisense oligonucleotides including eteplirsen, golodirsen, viltolarsen, and casimersen restore partial dystrophin in mutation-eligible patients. Delandistrogene moxeparvovec, an AAV-based gene therapy, delivers truncated functional dystrophin broadly across eligible patients. Givinostat, a first-in-class HDAC inhibitor approved for patients aged six and older, directly targets downstream fibrofatty muscle transformation, complementing dystrophin-restorative strategies. Cardiac surveillance, non-invasive ventilatory support, physiotherapy, and orthopaedic management are essential. Prognosis has improved considerably with modern multidisciplinary approaches; genetic counselling, psychological support, and family-centred education are integral to compassionate long-term management.

Key Highlights

• In Germany, prevalent DMD cases are projected to increase from 2,171 in 2025 to 2,193 by 2035.
• DMD is a rare, progressive neuromuscular disorder caused by dystrophin gene mutations, leading to irreversible muscle degeneration.
• Improved supportive care has increased survival, resulting in a larger adult DMD population.
• Gene therapies and mutation-targeted treatments are transforming the treatment landscape.

Market Overview

• The Germany DMD market is projected to grow from $294M in 2025 to $819M by 2035.
• Market growth is driven by:
• Uptake of high-cost gene and exon-skipping therapies
• Expanded treatment eligibility and improved diagnosis
• Future market value will be heavily influenced by next-generation genetic therapies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Solid Biosciences Inc.
• Sarepta Therapeutics, Inc.
• REGENXBIO Inc.
• Edgewise Therapeutics, Inc.
• Santhera Pharmaceuticals
• Daiichi Sankyo Co., Ltd.
• Pfizer
• Hoffmann-La Roche
• Insmed Gene Therapy LLC
• BioMarin Pharmaceutical
• Taiho Pharmaceutical Co., Ltd.
• Capricor Inc.
• NS Pharma, Inc.
• PTC Therapeutics
• Entrada Therapeutics, Inc.
• Satellos Bioscience, Inc.
• Dyne Therapeutics
• Nippon Shinyaku Co., Ltd.
• Avidity Biosciences, Inc.
• Cumberland Pharmaceuticals
• Precision BioSciences, Inc.
• Belief BioMed (Beijing) Co., Ltd.